1Dardari R, Khyatti M, Benider A, et al. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma [J].Int J Cancer, 2000, 86(1): 71-75. 被引量：1
3Feng P, Chan SH, Soo MY, et al. Antibody response to EpsteinBarr virus Rta protein in patients with nasopharyngeal carcinoma: a new serologic parameter for diagnosis [J]. Cancer, 2001, 92 (7):1872-1880. 被引量：1
4Chen MR, Liu MY, Hsu SM, et al. Use of bacterially expressed EBNA-1 protein cloned from a nasopharyngeal carcinoma (NPC) biopsy as a screening test for NPC patients[J].J Med Virol, 2001, 64(1): 51-57. 被引量：1
5Fachiroh J, Paramita DK, Hariwiyanto B, et al. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti- EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening [J]. J Clin Microbiol, 2006, 44(4): 1459-1467. 被引量：1
6Dardari R, Hinderer W, Lang D, et al. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138 [J]. J Clin Microbiol, 2001, 39(9): 3164- 3170. 被引量：1
7Chan KH, Gu YL, Ng F, et al. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma[J].IntJ Cancer, 2003, 106(6): 706-709. 被引量：1
8Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma [J]. N Engl J Med, 2004, 350(24) : 2461-2470. 被引量：1
9Chan KC, Lo YM. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma [J]. Semin Cancer Biol, 2002, 12(6): 489-496. 被引量：1
10Leung SF, Tam JS, Chan AT, et al. Improved accuracy of detection of nasopbaryngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody [J]. Clin Chem, 2004, 50(2): 339- 345. 被引量：1
7Al-Sarraf M, Leblanc M, Giri P G, et al. Chemoradiotherapy versus radiotherapy in patients with nasopharyngeal cancer:Phase Ⅲ randomized Intergroup study 0099 [J]. J Clin Oncol,1998,16(4) : 1310-1317. 被引量：1
8Chan A T, Ngan R, Teo P, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma[J]. J Natl Cancer Inst, 2005,97(7):536-539. 被引量：1
9Lee A W, Lau W H, Tung S Y, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group [J]. J Clin Oncol, 2005,23(28) :6966-6975. 被引量：1
10Zhang L, Zhao C, Peng P J, et al. Phase Ⅲ study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results[J]. J Clin Oncol, 2005,23 (33) : 8461-8468. 被引量：1
